Does This Provide a Reason to Sell Intercept Pharmaceuticals, Inc. (ICPT)? The Stock Has Formed Bearish Multiple Bottom Pattern

February 21, 2018 - By Winifred Garcia

Investors sentiment decreased to 1.33 in 2017 Q3. Its down 0.26, from 1.59 in 2017Q2. It worsened, as 33 investors sold Intercept Pharmaceuticals, Inc. shares while 30 reduced holdings. 30 funds opened positions while 54 raised stakes. 18.23 million shares or 10.01% less from 20.26 million shares in 2017Q2 were reported.
Pnc Financial Grp holds 0% in Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) or 1,311 shares. Fisher Asset Mgmt Limited Com invested in 13,436 shares or 0% of the stock. C World Wide Group Holdings A S holds 0% of its portfolio in Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) for 1,417 shares. Wells Fargo And Mn holds 93,910 shares. Spark Inv Mgmt Limited invested in 125,900 shares or 0.39% of the stock. Qs Invsts Limited Liability Corp reported 500 shares. Creative Planning invested 0% of its portfolio in Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT). Birchview Lp has 0.13% invested in Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) for 4,300 shares. Tekla Capital Mgmt Lc reported 123,200 shares stake. Susquehanna International Ltd Liability Partnership invested in 370,691 shares. Macquarie Ltd invested in 5,000 shares. Perceptive Advsr Llc accumulated 90,000 shares or 0.2% of the stock. Credit Agricole S A reported 17,000 shares. Orbimed Limited Liability Co holds 0.21% of its portfolio in Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) for 386,380 shares. Royal Financial Bank Of Canada reported 90,510 shares.

The stock of Intercept Pharmaceuticals, Inc. (ICPT) shows a multiple bottoms pattern with $57.74 target or 5.00 % below today’s $60.78 share price. The 6 months chart pattern indicates high risk for the $1.53 billion company. It was reported on Feb, 21 by Finviz.com. If the $57.74 price target is reached, the company will be worth $76.30M less.
Multiple bottoms are very good trading chart patterns. These patterns have a low break even failure rate and decent average rise in a bull market, giving them a solid performance rank. Back-tests of such patterns show that the break even failure rate is 4%, the average rise: 37%, the throwback rate: 64% and the percentage of stocks meeting their price targets: 64%.

The stock decreased 0.62% or $0.38 during the last trading session, reaching $60.78. About 642,853 shares traded. Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) has declined 14.52% since February 21, 2017 and is downtrending. It has underperformed by 31.22% the S&P500.

Analysts await Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) to report earnings on May, 3. They expect $-3.49 earnings per share, up 3.32 % or $0.12 from last year’s $-3.61 per share. After $-4.43 actual earnings per share reported by Intercept Pharmaceuticals, Inc. for the previous quarter, Wall Street now forecasts -21.22 % EPS growth.

Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) Ratings Coverage

Among 23 analysts covering Intercept Pharmaceuticals (NASDAQ:ICPT), 12 have Buy rating, 3 Sell and 8 Hold. Therefore 52% are positive. Intercept Pharmaceuticals has $423 highest and $45.0 lowest target. $154.49’s average target is 154.18% above currents $60.78 stock price. Intercept Pharmaceuticals had 73 analyst reports since August 10, 2015 according to SRatingsIntel. Cantor Fitzgerald initiated it with “Sell” rating and $58 target in Wednesday, July 6 report. Cantor Fitzgerald upgraded the shares of ICPT in report on Thursday, November 2 to “Neutral” rating. The firm has “Buy” rating given on Monday, January 22 by Credit Suisse. As per Tuesday, May 31, the company rating was maintained by JMP Securities. The rating was maintained by Oppenheimer on Wednesday, November 18 with “Outperform”. The stock of Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) earned “Outperform” rating by Wedbush on Wednesday, June 1. On Tuesday, September 12 the stock rating was maintained by Cantor Fitzgerald with “Sell”. The rating was maintained by Wedbush on Thursday, January 25 with “Buy”. Wedbush maintained Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) rating on Friday, December 30. Wedbush has “Outperform” rating and $224 target. The firm has “Buy” rating given on Tuesday, September 12 by Cowen & Co.

More recent Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) news were published by: Globenewswire.com which released: “Intercept Announces Updated US Prescribing Information for Ocaliva …” on February 01, 2018. Also Globenewswire.com published the news titled: “Intercept Announces Phase 3 REVERSE Trial Evaluating OCA for the Treatment of …” on February 12, 2018. Globenewswire.com‘s news article titled: “Intercept Pharmaceuticals Reports Full Year and Fourth Quarter 2017 Financial …” with publication date: February 14, 2018 was also an interesting one.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter: